Lantheus Holdings, Inc.
LNTH Healthcare Drug Manufacturers Specialty & Generic
Lantheus Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.5 billion, up 0.50% from fiscal 2024.
- Revenue
- +1.54%
- EPS
- −17.1%
- Free cash flow
- +7.71%
- Total debt
- +0.52%
Quarter to September 2026, against a year earlier
Follow LNTH
Alert me
Lantheus Holdings, Inc. (LNTH) EV/FCF
As of 5 November 2026, Lantheus Holdings, Inc. (LNTH) trades at a EV/FCF of 16.6×. Over the past ten years it has ranged from −79.5× (October 2015) to 334× (March 2021); the current reading is higher than 41% of that period.
EV/FCF, daily
Embed this chart
Annual newest first
| Period | EV/FCF | Change |
|---|---|---|
| FY2025 | 13.3× | 9.73% |
| FY2024 | 12.1× | 3.81% |
| FY2023 | 11.7× | (14.41%) |
| FY2022 | 13.6× | (61.28%) |
| FY2021 | 35.2× | (84.13%) |
| FY2020 | 222× | 1,334.68% |
| FY2019 | 15.4× | (13.54%) |
| FY2018 | 17.9× | (29.49%) |
| FY2017 | 25.3× | 162.28% |
| FY2016 | 9.7× | (79.59%) |
Quarterly newest first
| Period | EV/FCF | Change |
|---|---|---|
| Sep 2026 | 16.4× | (10.62%) |
| Jun 2026 | 18.3× | 40.70% |
| Mar 2026 | 13.0× | (1.82%) |
| Dec 2025 | 13.3× | 54.82% |
| 43 more quarters | Free account |
Against its own ten years
EV/FCF against peers
| Company | EV/FCF |
|---|---|
| AMRX AMNEAL PHARMACEUTICALS, INC. compare | −158× |
| AMLX Amylyx Pharmaceuticals, Inc. compare | −21.7× |
| LNTH Lantheus Holdings, Inc. | 16.6× |
| LQDA Liquidia Corporation compare | 25.6× |
| KNSA Kiniksa Pharmaceuticals International, plc compare | 32.2× |
| ALKS Alkermes plc compare | 36.0× |
| HIMS Hims & Hers Health, Inc. compare | 73.6× |
| RDY Dr. Reddy's Laboratories Ltd compare | 126× |
| SUPN Indivior Pharmaceuticals Inc. compare | 138× |
What EV/FCF is
EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))
More on LNTH
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement